Study S001408

Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06913023
Acronym: SPOT-DM
Study type: INTERVENTIONAL
Phase: PHASE2; PHASE3
Masking: NONE
Status: NOT_YET_RECRUITING
Enrollment: 37
Start: 2026-09-05
Primary completion: 2029-06-30
Lead sponsor: University Health Network, Toronto
Conditions: Kidney Transplant Recipient
Interventions: DRUG:Semaglutide 0.25 mg; DRUG:Semaglutide 0.5 mg; DRUG:Semaglutide 1.0 mg; DRUG:Semaglutide 1.7mg subcutaneous; DRUG:Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

2-hour OGTT [24 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.